Elevation Oncology Terminates Material Definitive Agreement
| Field | Detail |
|---|---|
| Company | Elevation Oncology, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, termination
TL;DR
Elevation Oncology just terminated a big deal. What was it?
AI Summary
Elevation Oncology, Inc. announced on June 26, 2025, the termination of a material definitive agreement. The company, formerly known as 14ner Oncology, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial standing.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals potential business disruptions or changes in strategy, which can introduce uncertainty.
Key Players & Entities
- Elevation Oncology, Inc. (company) — Registrant
- June 26, 2025 (date) — Date of earliest event reported
- 14ner Oncology, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Boston, Massachusetts (location) — Address of Principal Executive Offices
FAQ
What was the specific material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not specify which agreement it was.
What is the effective date of the termination?
The earliest event reported is June 26, 2025, which is the date of the report.
What are the potential consequences of this termination for Elevation Oncology?
The filing does not detail the specific consequences of the termination.
Was this termination a mutual decision or initiated by one party?
The filing does not provide details on whether the termination was mutual or unilateral.
Does this termination affect any ongoing clinical trials or product development?
The filing does not contain information regarding the impact on clinical trials or product development.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 2, 2025 regarding Elevation Oncology, Inc..